StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
EBM.V$0.86+11.69%
Fair $0.86+0.0%

EBM.V

Eastwood Bio-Medical Canada Inc.

Consumer Defensive / Food DistributionTSXV

$0.86

+0.09 (+11.69%)

Fairly Valued+0.0%Fair Value $0.86Fund rank 26/100 · Data gapFallback financials|
SA 32/D
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-15217.00 · quality 45.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

32/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · EBM.VLocal privado en este navegador · Eastwood Bio-Medical Canada Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$59M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

20.4%

↑

Gross Margin

70.5%

↑

Debt/Equity

-0.05

↓
52-Week Range$1
$0$1

TradingView lightweight chart

EBM.V price, volumen y niveles de valoración

Último $0.860Periodo -65.6%
Fair value: $0.860

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-15.6%

FCF CAGR

—

FCF margin

2.5%

FCF / Net income

-0.06x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $782080.0 · net income $-332767.0 · FCF $19303.0

2022-FY → 2025-FY

Gross margin

70.5%+1.0% pts

Operating margin

-37.4%-27.4% pts

Net margin

-42.5%-31.0% pts

FCF margin

2.5%+3.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$782080.00$782080.00$702076.00$867936.00$1.3M
Net Income$-332767.00$-332767.00$-455870.00$-546598.00$-149879.00
EBITDA$-247365.00$-247365.00$-330158.00$-410582.00$-32323.00
EPS-0.01-0.01-0.01-0.01-0.00
Gross Margin70.5%70.5%64.7%63.2%69.5%
Operating Margin-37.4%-37.4%-62.3%-58.2%-10.0%
Net Margin-42.5%-42.5%-64.9%-63.0%-11.5%
Balance Sheet
Debt/Equity-0.05-0.05-0.06-0.07-0.21
Current Ratio0.040.04———
Cash Flow
Free Cash Flow$19303.00$19303.00$-15217.00$-16888.00$-7299.00
Returns
ROE20.4%20.4%35.2%65.0%50.9%
Growth & Yield
Revenue Growth11.4%11.4%-19.1%-33.2%—
EPS Growth0.0%0.0%0.0%-359.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +115.0%

Total return

+115.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → -0.01

Residual

+115.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+115.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.